GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AXM Pharma Inc (GREY:AXMP) » Definitions » Piotroski F-Score

AXMP (AXM Pharma) Piotroski F-Score : 0 (As of Apr. 28, 2025)


View and export this data going back to 2001. Start your Free Trial

What is AXM Pharma Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

AXM Pharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for AXM Pharma's Piotroski F-Score or its related term are showing as below:


AXM Pharma Piotroski F-Score Historical Data

The historical data trend for AXM Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXM Pharma Piotroski F-Score Chart

AXM Pharma Annual Data
Trend Jun01 Jun02 Dec03 Dec04 Dec05
Piotroski F-Score
- - - - 4.00

AXM Pharma Semi-Annual Data
Jun01 Jun02 Dec03 Dec04 Dec05
Piotroski F-Score - - - - 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec05) TTM:Last Year (Dec04) TTM:
Net Income was $-11.09 Mil.
Cash Flow from Operations was $-8.61 Mil.
Revenue was $2.02 Mil.
Gross Profit was $0.77 Mil.
Average Total Assets from the begining of this year (Dec04)
to the end of this year (Dec05) was (12.341 + 13.729) / 2 = $13.035 Mil.
Total Assets at the begining of this year (Dec04) was $12.34 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $4.06 Mil.
Total Current Liabilities was $9.64 Mil.
Net Income was $-13.99 Mil.

Revenue was $2.12 Mil.
Gross Profit was $1.07 Mil.
Average Total Assets from the begining of last year (Dec03)
to the end of last year (Dec04) was (11.025 + 12.341) / 2 = $11.683 Mil.
Total Assets at the begining of last year (Dec03) was $11.03 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $3.73 Mil.
Total Current Liabilities was $5.35 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

AXM Pharma's current Net Income (TTM) was -11.09. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

AXM Pharma's current Cash Flow from Operations (TTM) was -8.61. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec04)
=-11.088/12.341
=-0.89846852

ROA (Last Year)=Net Income/Total Assets (Dec03)
=-13.99/11.025
=-1.26893424

AXM Pharma's return on assets of this year was -0.89846852. AXM Pharma's return on assets of last year was -1.26893424. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

AXM Pharma's current Net Income (TTM) was -11.09. AXM Pharma's current Cash Flow from Operations (TTM) was -8.61. ==> -8.61 > -11.09 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec05)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec04 to Dec05
=0/13.035
=0

Gearing (Last Year: Dec04)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec03 to Dec04
=0/11.683
=0

AXM Pharma's gearing of this year was 0. AXM Pharma's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec05)=Total Current Assets/Total Current Liabilities
=4.06/9.64
=0.42116183

Current Ratio (Last Year: Dec04)=Total Current Assets/Total Current Liabilities
=3.731/5.347
=0.69777445

AXM Pharma's current ratio of this year was 0.42116183. AXM Pharma's current ratio of last year was 0.69777445. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

AXM Pharma's number of shares in issue this year was 20.434. AXM Pharma's number of shares in issue last year was 16.067. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.772/2.022
=0.3818002

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.065/2.116
=0.50330813

AXM Pharma's gross margin of this year was 0.3818002. AXM Pharma's gross margin of last year was 0.50330813. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec04)
=2.022/12.341
=0.1638441

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec03)
=2.116/11.025
=0.19192744

AXM Pharma's asset turnover of this year was 0.1638441. AXM Pharma's asset turnover of last year was 0.19192744. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

AXM Pharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

AXM Pharma  (GREY:AXMP) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


AXM Pharma Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of AXM Pharma's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


AXM Pharma Business Description

Traded in Other Exchanges
N/A
Address
3651 Lindell Road, Suite D344, Las Vegas, NV, USA, 89103
AXM Pharma Inc is a pharmaceutical company producing, marketing and distributing pharmaceutical products in China. It produces, and distributes medicines in various dosages and forms in most areas of medicinal treatment, as well as herbal remedies.

AXM Pharma Headlines

From GuruFocus

AXM Pharma Issues Correction

By Marketwired Marketwired 07-07-2018

AXM Pharma Issues Correction

By GlobeNewswire GlobeNewswire 07-07-2018